[The "cost-benefit" analysis of new antiepileptic drugs].
The objective was to optimize the pharmaceutical treatment of epileptic patients and to evaluate the clinical-economical effectiveness of new antiepileptic drugs (AED)--levetiracetam, lamotrigine, topiramate and oxcarbazepine. The study included 134 patients with different types of seizures who received earlier antiepileptics with the addition of new AED as mono- or polytherapy. The cost of treatment and pharmacoeconomic "cost-benefit" index were calculated before and after the treatment optimization. After one year of the treatment with "news" AED, the decrease in seizure frequency was 75-92%. The "cost-benefit" ratio was significantly (p < 0.05) decreased by 2-3 times in all types of seizures despite the increase of direst costs of the treatment. The significant (p < 0.05) decrease in the cost of treatment of epilepsy was noted in all groups studied. In conclusion, the rational treatment using "new" AED allows to reduce both the total cost of treatment and ccost-benefits ratio.